Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509108 | 1.00 | MEN1 (0.34) | MEN1POLBGAAKMT2AESR1 | |
| SCHEMBL899576 | 0.99 | MEN1 (0.35) | MEN1POLBGAAKMT2AESR1 | |
| SCHEMBL899818 | 0.88 | MEN1 (0.38) | MEN1POLBGAAKMT2AESR1 | |
| SCHEMBL8509258 | 0.85 | — | — | |
| SCHEMBL8509163 | 0.85 | — | — | |
| SCHEMBL899790 | 0.85 | ESR1 (0.35) | MEN1POLBGAAKMT2AESR1 | |
| SCHEMBL899718 | 0.84 | MEN1 (0.38) | MEN1POLBGAAKMT2AESR1 | |
| SCHEMBL899756 | 0.79 | GAA (0.36) | MEN1POLBGAAKMT2AESR1 | |
| SCHEMBL899951 | 0.79 | MEN1 (0.41) | MEN1POLBGAAKMT2AESR1 | |
| SCHEMBL8509481 | 0.78 | MEN1 (0.50) | MEN1POLBGAAKMT2AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | claimed |
| US-20130323640-A1 | Preparation of Norbornane-based PAC Ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2013-12-05 | — | — | US | claimed |
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20130323640-A1 | Preparation of Norbornane-based PAC Ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2013-12-05 | — | — | US | disclosed |
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | NBAS, PHB2, BDNF | MEN1 2147/4885POLB 137/4885GAA 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.